National and Kapodistrian University of Athens
Μελέτη της επίδρασης νευροενδοκρινικών και ψυχοανοσολογικών παραμέτρων σε κρίσιμα στάδια θεραπευτικής αντιμετώπισης του μείζονος καταθλιπτικού επεισοδίου
Abstract
dc:descriptionThere is a body of evidence implicating inflammatory mediators to the pathophysiology of MajorDepression Disorder (MDD). Inflammatory cytokines have been shown to interact withneurotransmitters’ metabolism, neuroendocrine function and neural plasticity.The aim of this study was the investigation of the interaction of immune mediators with the metabolismof tryptophan, the neural plasticity and the endocrine function as well as their changes relevant toantidepressive treatment in MDD patients. We assessed inflammatory cytokines IFN-γ, TNF-α, PGE2,anti-inflammatory IL-4, the rate-limiting enzyme of tryptophan metabolism 2,3-dioxygenase ofindoleamine (IDO), serotonin, 5-hydroxy-indoloacetic acid (5-HIAA) and brain-derived neurotrophicfactor (BDNF) by enzyme-linked immunosorbent assay (ELISA). Moreover, C-reactive protein (CRP)was determined using high sensitive immunonephelometry. Cortisol and prolactin were determinedusing luminescence technique. Forty female patients suffering from MDD and forty controls (age, sexand body mass index matched) participated. The study was carried out in the Women’s Inpatients Unitof Eginition Hospital. On admission and before discharging from hospital patients were rated on theHamilton Scale and blood samples were collected. 20 of the patients underwent a six weekpharmacological antidepressant treatment, although the other 20 underwent a series of 8-12 ECTsessions. All patients had successfully remitted.Our findings showed that inflammatory mediator and IDO were significantly higher in patients,compared to controls and were strongly positive correlated. Cortisol and prolactin concentrations werealso elevated in patients. Serotonin and BDNF levels were significantly lower than the controlsrespectively and they both showed strong negative correlation with IDO. Post- treatment IDO and TNF-α levels decreased significantly, while IFN-γ, PGE2, CRP and IL-4 did not change. CRP concentrationswere reduced significantly in pharmacotherapy group only. Post-treatment Cortisol and prolactin levelswere also decreased after treatment. Furthermore, serotonin and BDNF levels showed an increase,though not significant.Our findings support the hypothesis that in MDD inflammatory mediators affect tryptophan metabolism,through induction of IDO production, resulting in reduced serotonin production. The induced IDOproduction that leads tryptophan metabolism to overproduction of neurodegenerative metabolites couldcontribute to the reduction of neurotrophic support and probably to the reduced BDNF production,along with the increased pre-treatment cortisol levels of patients. The marked higher levels of IDO inMDD and the co-variation of IDO changes with patients’ clinical improvement, under successfulantidepressive treatment suggests that IDO plays an important role in the pathophysiology of MDD andthat effective antidepressive therapy of various modalities reduces IDO production. Finally, theassessment of IDO serum concentrations by ELISA, a novel approach in measuring IDO in MDDpatients under treatment, might be a useful peripheral marker in MDD.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Zogka, Margarita
- Ζόγκα, Μαργαρίτα
Subjects
dc:subject × 16- Ψυχοανοσολογικές παράμετροι
- Μείζονα κατάθλιψη
- Μεταβολισμός τρυπτοφάνης
- Φλεγμονώδεις παράγοντες
- Αντικαταθλιπτική θεραπεία
- Psychoimmunological parameters
- Major depression
- Tryptophan metabolism
- Inflammatory mediators
- Antidepressive treatment
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Επιστήμες Υγείας
- Medical and Health Sciences
- Clinical Medicine
- Health Sciences
Rights
dc:rights- Statement dc:rights
-
- BY_NC_SA
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41089